BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-469@pharmaconomics
DTSTAMP:20260707T021627Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:RVPH Phase 3 — brilaroxazine (estimated date)
DESCRIPTION:Phase 3 trial results for brilaroxazine in schizophrenia are due ~ Mar 31\, 2027. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1742927/000143774926012303/rvph20260414_8k.htm\n\nTrack it: https://pharmaconomics.com/e/469
URL:https://pharmaconomics.com/e/469
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:RVPH catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR